Stock Repurchase by IVRO’s Management Shows Increased Confidence in Future of Non-Animal Testing
Placentia, California–(Newsfile Corp. – March 30, 2022) – InVitro International (OTC PINK: IVRO), a 30+ year leader in providing non-animal testing methods, today announced it has completed the re-purchase of 100,000 shares of its common stock. The terms of this transaction were negotiated in December 2021 with a long-term shareholder.
IVRO President, Atul Jhalani, said “I believe our decision reflects IVRO management’s continuing strong belief in the future of NON-Animal testing; worthy of special note, just recently “The Humane Cosmetics Act of 2021″ arrived on the floor of the U.S. Congress after many years in Committee. So, our demonstrated enthusiasm is added to that of millions of animal welfare supporters here and around the world. Looking forward, it seems very reasonable to envision in vitro tests increasingly replacing the use of animals. In addition to faster, lower cost safety testing results, more companies now will be able to add kindness to animals as a side benefit of any new formulations.”
Chairman and CEO, W. Richard Ulmer, added: “Today we follow a FY ’21 stated intention to share more of what and how we do things at InVitro International. A first step in the above transaction required our IVRO Board of Directors to agree that the purchase of these 100,000 shares was a timely and prudent investment, given our cash-rich balance sheet. Next, we required our auditor’s pronouncement that these shares when re-purchased remain authorized for issuance. This provided us with confidence that we could find future ways to use them to the benefit of all shareholders. Finally, the purchase was consummated this month.”
To be added to the Company’s email list please click this link or for additional information, please call our investor relations department at 818-926-5441.
About InVitro International, Inc.
InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology-driven provider of non-animal testing methods. The Company’s testing technologies are designed to produce data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO’s technology is commercialized globally through test kits and partner laboratory services.
(This press release may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward looking statements. These risks and uncertainties include but are not limited to: acceptance of the Company’s technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.)
Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com
www.invitrointl.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/118593